Research Article
Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet
Figure 1
Liraglutide attenuates nonalcoholic fatty liver disease, retains intestinal barrier function, and decreases inflammation levels in rats on a high-fat diet. (a) Oil Red O staining of liver sections; (b) body weight of rats; (c) relative levels of triglycerides (TG) in the liver; (d) levels of serum alanine transaminase (ALT), (e) aspartate transaminase (AST), (f) tumor necrosis factor-α (TNF-α), (g) lipopolysaccharide (LPS), and (h) diamine oxidase (DAO); (i) ultrastructure of tight junctions in the ileal mucosa (transmission electron microscopy, 20,000x). Data are expressed as mean ± standard deviation values. vs NC group; vs NC group; vs HFD group; vs HFD group.
| (a) |
| (b) |
| (c) |
| (d) |
| (e) |
| (f) |
| (g) |
| (h) |
| (i) |